Nanotechnology and malaria: Evaluation of efficacy and toxicity of green nanoparticles
J Vector Borne Dis. 2024 Apr 12. doi: 10.4103/JVBD.JVBD_175_23. Online ahead of print.ABSTRACTMalaria is a global health problem that causes 1.5-2.7 million deaths worldwide each year. Resistance to antimalarial drugs in malaria parasites and to insecticides in vectors is one of the most serious issues in the fight against the disease. Moreover, the lack of an effective vaccine against malaria is still a major concern. Recent developments in nanotechnology have resulted in new prospects for the fight against malaria, especially by obtaining metal nanoparticles (NPs) that are less toxic, highly biocompatible, environmentall...
Source: Journal of Vector Borne Diseases - April 18, 2024 Category: Infectious Diseases Authors: Ana Barati Ayan Huseynzade Nergiz Imamova Inji Shikhaliyeva Sedanur Keles Jahid Alakbarli Bu şra Akgul Melahat Bagirova Adil M Allahverdiyev Source Type: research
Factors associated with malaria vaccine uptake in Nsanje district, Malawi
Malaria remains a significant global health burden affecting millions of people, children under 5 years and pregnant women being most vulnerable. In 2019, the World Health Organization (WHO) endorsed the intro... (Source: Malaria Journal)
Source: Malaria Journal - April 17, 2024 Category: Infectious Diseases Authors: Atusaye J. Simbeye, Save Kumwenda, Lauren M. Cohee, Dickens Omondi, Peninah K. Masibo, Hesborn Wao and Shehu S. Awandu Tags: Research Source Type: research
Plans to expand African vaccine production face steep hurdles
In March 2022, when the pandemic was still raging, the messenger RNA (mRNA) company Moderna announced it would build a $500 million plant in Kenya to manufacture half a billion doses of its COVID-19 vaccine annually. “
This is major
,” Kenyan President William Ruto said at the time. The plant would help reduce Africa’s dependence on vaccines produced elsewhere, Ruto said—a situation that had turned disastrous during the pandemic—and bring economic benefits as well.
But Moderna may never break ground on the Kenya factory. On 11 April, the company said it had
“paused its efforts”
becau...
Source: Science of Aging Knowledge Environment - April 16, 2024 Category: Geriatrics Source Type: research
Recent advances in immunotherapies against infectious diseases
Immunother Adv. 2020 Nov 25;1(1):ltaa007. doi: 10.1093/immadv/ltaa007. eCollection 2021 Jan.ABSTRACTImmunotherapies are disease management strategies that target or manipulate components of the immune system. Infectious diseases pose a significant threat to human health as evidenced by countries continuing to grapple with several emerging and re-emerging diseases, the most recent global health threat being the SARS-CoV2 pandemic. As such, various immunotherapeutic approaches are increasingly being investigated as alternative therapies for infectious diseases, resulting in significant advances towards the uncovering of path...
Source: Cancer Control - April 16, 2024 Category: Cancer & Oncology Authors: Dharanidharan Ramamurthy Trishana Nundalall Sanele Cingo Neelakshi Mungra Maryam Karaan Krupa Naran Stefan Barth Source Type: research
A targetable receptor-binding site on PfCyRPA to aid in the fight against malaria
Trends Parasitol. 2024 Apr 10:S1471-4922(24)00083-7. doi: 10.1016/j.pt.2024.04.001. Online ahead of print.ABSTRACTRecently, Day et al. identified a receptor-binding site on the malaria parasite protein PfCyRPA that binds the host sugar Neu5Ac, and they found that disrupting this interaction impedes parasite growth. A map of the receptor-binding site identifies an attractive target for antimalarial vaccines and therapeutics.PMID:38604871 | DOI:10.1016/j.pt.2024.04.001 (Source: Trends in Parasitology)
Source: Trends in Parasitology - April 11, 2024 Category: Parasitology Authors: Thayne H Dickey Niraj H Tolia Source Type: research
A systematic review on malaria and dengue vaccines for the effective management of these mosquito borne diseases: Improving public health
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - April 11, 2024 Category: Allergy & Immunology Authors: Hind M. Al-OsaimiMohammed KananLujain MarghlaniBadria Al-RowailiReem AlbalawiAbrar SaadSaba AlasmariKhaled AlthobaitiZainab AlhulailiAbeer AlanziRawan AlqarniRazan AlsofiyaniReem Shrwania Department of Pharmacy Services Administration, King Fahad Medical Source Type: research
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-na ïve adults
CONCLUSION: Co-administration of RTS,S and FMP1/AS02 reduced anti-RTS,S antibody, but did not affect tolerability, cellular immunity, or efficacy in a stringent CHMI model. Absence of efficacy or delay of patency in the sporozoite challenge model in the FMP1/AS02 group did not rule out efficacy of FMP1/AS02 in an endemic population. However, a Phase IIb trial of FMP1/AS02 in children in malaria-endemic Kenya did not demonstrate efficacy against natural infection.CLINICALTRIALS: gov identifier: NCT01556945.PMID:38584058 | DOI:10.1016/j.vaccine.2024.03.072 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: J F Cummings M E Polhemus K E Kester C F Ockenhouse R A Gasser P Coyne G Wortmann R K Nielsen K Schaecher C A Holland U Krzych N Tornieporth L A Soisson E Angov D G Heppner RTS,S Vaccine Evaluation Group Source Type: research
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-na ïve adults
CONCLUSION: Co-administration of RTS,S and FMP1/AS02 reduced anti-RTS,S antibody, but did not affect tolerability, cellular immunity, or efficacy in a stringent CHMI model. Absence of efficacy or delay of patency in the sporozoite challenge model in the FMP1/AS02 group did not rule out efficacy of FMP1/AS02 in an endemic population. However, a Phase IIb trial of FMP1/AS02 in children in malaria-endemic Kenya did not demonstrate efficacy against natural infection.CLINICALTRIALS: gov identifier: NCT01556945.PMID:38584058 | DOI:10.1016/j.vaccine.2024.03.072 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: J F Cummings M E Polhemus K E Kester C F Ockenhouse R A Gasser P Coyne G Wortmann R K Nielsen K Schaecher C A Holland U Krzych N Tornieporth L A Soisson E Angov D G Heppner RTS,S Vaccine Evaluation Group Source Type: research
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-na ïve adults
CONCLUSION: Co-administration of RTS,S and FMP1/AS02 reduced anti-RTS,S antibody, but did not affect tolerability, cellular immunity, or efficacy in a stringent CHMI model. Absence of efficacy or delay of patency in the sporozoite challenge model in the FMP1/AS02 group did not rule out efficacy of FMP1/AS02 in an endemic population. However, a Phase IIb trial of FMP1/AS02 in children in malaria-endemic Kenya did not demonstrate efficacy against natural infection.CLINICALTRIALS: gov identifier: NCT01556945.PMID:38584058 | DOI:10.1016/j.vaccine.2024.03.072 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: J F Cummings M E Polhemus K E Kester C F Ockenhouse R A Gasser P Coyne G Wortmann R K Nielsen K Schaecher C A Holland U Krzych N Tornieporth L A Soisson E Angov D G Heppner RTS,S Vaccine Evaluation Group Source Type: research
A paradigm for Africa-centric vaccine development in Equatorial Guinea
Trends Parasitol. 2024 Apr 5:S1471-4922(24)00072-2. doi: 10.1016/j.pt.2024.03.005. Online ahead of print.ABSTRACTThe Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development of vaccines in Africa, for Africa. We review achievements and challenges of this pioneering, award-winning, public-private partnership which offers a model for future Africa-centric clinical research and development (R&D).PMID:38582683 | DOI:10.1016/j.pt.2024.03.005 (Source: Trends in Parasitology)
Source: Trends in Parasitology - April 6, 2024 Category: Parasitology Authors: Peter F Billingsley Thomas L Richie Salim Abdulla Mitoha Ondo'o Ayekaba Claudia A Daubenberger Gu íllermo A Garcia Stephen L Hoffman Source Type: research
A paradigm for Africa-centric vaccine development in Equatorial Guinea
Trends Parasitol. 2024 Apr 5:S1471-4922(24)00072-2. doi: 10.1016/j.pt.2024.03.005. Online ahead of print.ABSTRACTThe Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development of vaccines in Africa, for Africa. We review achievements and challenges of this pioneering, award-winning, public-private partnership which offers a model for future Africa-centric clinical research and development (R&D).PMID:38582683 | DOI:10.1016/j.pt.2024.03.005 (Source: Trends in Parasitology)
Source: Trends in Parasitology - April 6, 2024 Category: Parasitology Authors: Peter F Billingsley Thomas L Richie Salim Abdulla Mitoha Ondo'o Ayekaba Claudia A Daubenberger Gu íllermo A Garcia Stephen L Hoffman Source Type: research
A paradigm for Africa-centric vaccine development in Equatorial Guinea
Trends Parasitol. 2024 Apr 5:S1471-4922(24)00072-2. doi: 10.1016/j.pt.2024.03.005. Online ahead of print.ABSTRACTThe Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development of vaccines in Africa, for Africa. We review achievements and challenges of this pioneering, award-winning, public-private partnership which offers a model for future Africa-centric clinical research and development (R&D).PMID:38582683 | DOI:10.1016/j.pt.2024.03.005 (Source: Trends in Parasitology)
Source: Trends in Parasitology - April 6, 2024 Category: Parasitology Authors: Peter F Billingsley Thomas L Richie Salim Abdulla Mitoha Ondo'o Ayekaba Claudia A Daubenberger Gu íllermo A Garcia Stephen L Hoffman Source Type: research
A paradigm for Africa-centric vaccine development in Equatorial Guinea
Trends Parasitol. 2024 Apr 5:S1471-4922(24)00072-2. doi: 10.1016/j.pt.2024.03.005. Online ahead of print.ABSTRACTThe Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development of vaccines in Africa, for Africa. We review achievements and challenges of this pioneering, award-winning, public-private partnership which offers a model for future Africa-centric clinical research and development (R&D).PMID:38582683 | DOI:10.1016/j.pt.2024.03.005 (Source: Trends in Parasitology)
Source: Trends in Parasitology - April 6, 2024 Category: Parasitology Authors: Peter F Billingsley Thomas L Richie Salim Abdulla Mitoha Ondo'o Ayekaba Claudia A Daubenberger Gu íllermo A Garcia Stephen L Hoffman Source Type: research
A paradigm for Africa-centric vaccine development in Equatorial Guinea
Trends Parasitol. 2024 Apr 5:S1471-4922(24)00072-2. doi: 10.1016/j.pt.2024.03.005. Online ahead of print.ABSTRACTThe Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development of vaccines in Africa, for Africa. We review achievements and challenges of this pioneering, award-winning, public-private partnership which offers a model for future Africa-centric clinical research and development (R&D).PMID:38582683 | DOI:10.1016/j.pt.2024.03.005 (Source: Trends in Parasitology)
Source: Trends in Parasitology - April 6, 2024 Category: Parasitology Authors: Peter F Billingsley Thomas L Richie Salim Abdulla Mitoha Ondo'o Ayekaba Claudia A Daubenberger Gu íllermo A Garcia Stephen L Hoffman Source Type: research
Malaria Therapeutic Paradigm: An Evolution Towards Commercial Drug Delivery Technology
In this study, we are going to discuss about the seminal delivery systems for drug which are in lab, market, and clinical trials for treatment of malaria. Also, we focused on the commercial and conventional drug delivery systems which can be more effective and the challenges behind their success. (Source: Current Treatment Options in Infectious Diseases)
Source: Current Treatment Options in Infectious Diseases - April 5, 2024 Category: Infectious Diseases Source Type: research
